<DOC>
	<DOC>NCT00726180</DOC>
	<brief_summary>The majority pf breast cancers present as ER-positive, many of which are able to be targeted with multiple hormonal therapies. Altering ER-negative tumors to increase ER expression has the potential to benefit patients by making hormonal therapies a therapeutic option and possibly improving their overall prognosis.</brief_summary>
	<brief_title>Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Women who have Her2 positive and ER negative or ERlow breast cancer that has not metastasized, or spread to other parts of the body, are eligible for the study. Participants must have had either a core biopsy or incisional biopsy of their breast cancer, but not yet had definitive breast surgery, including lumpectomy or mastectomy. Participants may not have had a BRCA mutation found on genetic testing. Participants should have not yet received treatment for their breast cancer, including: chemotherapy, hormonal therapy, trastuzumab.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Women</keyword>
	<keyword>w/Her2</keyword>
	<keyword>positive</keyword>
	<keyword>ERnegative</keyword>
	<keyword>not metastasized</keyword>
</DOC>